Fig. 2From: A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancerBaseline and follow-up CT scans. Baseline (a) and follow-up (b) CT scans of a 43-year-old patient with left chest wall soft tissue metastasesBack to article page